Is Vascular Biogenics Ltd. overvalued or undervalued?

As of 28 March 2019, the valuation grade for Vascular Biogenics Ltd. moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. The company appears to be overvalued given its current financial metrics, including a P/E ratio of -0.0001 and an EV to EBITDA of 0.28, which are both indicative of severe financial distress. Additionally, the negative ROE of -170.61% further underscores the challenges the company faces.
In comparison to its peers, Vascular Biogenics Ltd. has a significantly lower P/E ratio than Equillium, Inc. at -5.5396 and OncoCyte Corp. at -2.9218, both of which are also categorized as risky. The company's returns have been dismal, with a year-to-date decline of -99.64% compared to a 12.22% gain in the S&P 500, reinforcing the notion that it is not a viable investment at this time.